FDA Tentatively Approves First Generic Lenacapavir Injection for HIV Prevention at $40 a Year

The US Food and Drug Administration granted tentative approval on November 2, 2026, to the first generic version of injectable lenacapavir for HIV pre-exposure prophylaxis. The product, manufactured by Dr. Reddy’s Laboratories, is intended for the 120 low- and middle-income countries covered by Gilead Sciences’ voluntary licensing program and is expected to cost $40 per person per year.

Tentative approval is the FDA’s designation for a generic while the originator remains under patent. It does not authorize sales inside the United States but makes the product eligible for purchase by the US government and often accelerates regulatory reviews in other countries. Gilead’s branded product, marketed as Yeztugo in the United States, received approval in June 2025 and carries a list price of $28,218 per year. The generic timeline of 16 months from originator approval is among the shortest on record for a major HIV innovation.

Lenacapavir is administered twice yearly by injection. Two large studies showed it nearly eliminated new infections among people at high risk. More than 125,000 people in Africa have already started on the originator product. Neil Buddy Shah, CEO of the Clinton Health Access Initiative, said the approval brings the drug closer to millions more at the $40 annual price, matching the cost of existing daily oral PrEP pills while requiring far fewer doses.

Unitaid, the Clinton Health Access Initiative, and Wits RHI worked with Dr. Reddy’s on pricing, technical support, and regulatory strategy. Initial supplies are expected to reach countries before the end of 2026, with broader availability in 2027. Zambia is among the first destinations mentioned, with hopes of deliveries by World AIDS Day on December 1. The FDA pathway used is the long-standing mechanism that verifies quality for HIV drugs supplied by the US government to other countries.

Gilead’s voluntary license allows generic production for the designated countries while protecting the US market. The $40 price was set in a September 2025 agreement that combined an early pricing commitment with financial and technical assistance. Officials involved said the rapid generic approval demonstrates what is possible when access is prioritized from the start rather than deferred for a decade.

The injectable form addresses adherence challenges that limit the effectiveness of daily oral PrEP in many settings. Because the shot is needed only twice a year, it reduces the number of clinic visits and the risk of missed doses. Health programs in the 120 countries will still need to build delivery capacity, cold-chain logistics where required, and counseling systems. The approval itself does not solve those operational steps, but it removes the patent and pricing barrier that previously limited scale.

No vaccine for HIV exists. Public health organizations have described the twice-yearly injectable as the closest current tool to a vaccine for high-risk populations. The combination of high efficacy in trials, the $40 price point, and the 16-month generic timeline sets a new benchmark for how quickly a prevention product can move from originator approval to broad availability in low- and middle-income countries.